Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

88.23 -0.65 (-0.73%)

Streaming Delayed Price Updated: 3:08 PM EDT, Mar 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	456,813
Open	89.42
Bid (Size)	87.97 (100)
Ask (Size)	88.24 (100)
Prev. Close	88.88
Today's Range	87.98 - 90.18
52wk Range	36.88 - 109.28
Shares Outstanding	38,297,975
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Performance

YTD	+13.0%	+13.0%
1 Month	-17.9%	-17.9%
3 Month	+11.3%	+11.3%
6 Month	+19.9%	+19.9%
1 Year	+90.6%	+90.6%

More News

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

March 16, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗

February 25, 2026

Via Chartmill

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗

February 14, 2026

Via Chartmill

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗

February 10, 2026

Via Chartmill

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 12, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience

March 05, 2026

Via MarketMinute

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

March 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update

February 25, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗

February 25, 2026

Via The Motley Fool

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

February 23, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

February 18, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

February 05, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗

January 31, 2026

Via The Motley Fool

Is Mirum Pharmaceuticals About to Soar in 2026? ↗

January 27, 2026

Via The Motley Fool

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

January 26, 2026

From Mirum Pharmaceuticals, Inc.

Via Business Wire

A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)

January 13, 2026

Via PredictStreet

3 Top Growth Stocks to Buy in the First Half of 2026 ↗

January 13, 2026

Via The Motley Fool

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?

Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?

The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market

What is the current price of Mirum Pharmaceuticals, Inc. - common stock?

The current price of Mirum Pharmaceuticals, Inc. - common stock is 88.23

When was Mirum Pharmaceuticals, Inc. - common stock last traded?

The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 03/27/26 03:08 PM ET

What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?

The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 3.38B

How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?

Mirum Pharmaceuticals, Inc. - common stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.